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The ability to assess the efﬁcacy and effectiveness of an intervention for the treatment of hip osteoar-
thritis (OA) requires strong clinical trial methodology. This consensus paper provides recommendations
based on a narrative literature review and best judgment of the members of the committee for clinical
trials of hip OA. We provide recommendations on clinical trial design, outcome measures, including
structural (radiography), and patient and physician global assessments, performance based measures,
molecular markers and experimental endpoints including MRI imaging. This information can be utilized
by sponsors of trials for new therapeutic agents for hip OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Over the past decade, there have been important advances in the
understandingof thepathophysiologyof osteoarthritis (OA), including
OA of the hip. In addition, there are a number of novel therapeutic
agents that are being evaluated for the treatment of hip OA. Since hip
OA can affect up to 10% of the elderly population, there is a signiﬁcant
need to develop strong methodology for clinical trials of hip OA1.
The Osteoarthritis Research Society International (OARSI)
established a Task Force to address the issue of clinical trial
guidelines for OA in 20122. The intent of the Task Force was to bring
together the ideas of academic and clinical physicians, epidemiol-
ogists, researchers in the pharmaceutical industry and other
interested experts on the conduct of clinical trials generated by the
relevant active working groups, and to add sufﬁcient detail to be of
help to any party involved in the design of clinical trials2. This paper
serves to update the recommendations for clinical trials in patients
with hip OA published in 19962 by providing recommendations on
clinical trial design, outcome measures, and an assessment ofto: N.E. Lane, University of
A 95817, USA.
ternational. Published by Elsevier Lsymptom modifying medications trials. Issues regarding imaging
are considered both herein as well as in an accompanying article on
hip OA imaging in this issue.
The methodology that the group utilized to develop these rec-
ommendations is now described. Initially our group had one group
meeting. This was followed by a series of teleconferences. All group
members reviewed both the individual sections of the recom-
mendations and the entire manuscript and provided feedback.
Many of the recommendations are evidence-based and supported
by the published literature; the remainder are based on best
judgment of the members of the committee.Different trial objectives for hip OA
Osteoarthritis of the hip is a signiﬁcant problem in the U.S. and
Europe, with nearly 7e15% of elderly subjects with radiographic
and clinical manifestations of the disease. Patients with hip OA are
at increased risk for pain onmovement, weight bearing pain as well
as nighttime pain. This commonly leads to loss of function,
increased isolation and with decreased activity an increased risk of
hypertension, cardiovascular disease and death. Patients are more
likely to seek medical care in the setting of symptoms as well astd. All rights reserved.
Table I
Recommended requirements for the study protocol
Deﬁnition of the Investigators and their roles in the study
Study Sites
Method of Randomization
Patient monitoring procedures
Technical aspects of Imaging Techniques
Laboratory tests
Methods to Document Adverse Events
Method of Blinding
Documentation of Medication Intake
Method of Maintaining the Medication Log for each Participating Center
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measuring the importance of pain and how it relates to functional
status is a critical component of the outcomes to be measured in
clinical trials of interventions to treat symptomatic hip OA3.
Standard trial designs
Standard trial designs for measurement of these outcomes
include parallel-group, randomized controlled trials (RCTs)
comparing study intervention with placebo or standard of care
(SOC) and can be designed as superiority or non-inferiority trials.
Randomized withdrawal trials in which an active intervention is
compared to a group of subjects that were randomly withdrawn
from the intervention have also been used. . Open-label experi-
ences may be informative, but the importance of randomization
and blinding cannot be overemphasized. Furthermore, good study
conduct is crucial for an understandable outcome. It is critical to
minimize missing data; an intention to treat analysis is usually
required, particularly for drug or device regulatory approvals, and
for applying instruments for measured outcomes, which are vali-
dated and well understood.
For clinical trials to be used for pivotal approval for drugs to treat
the signs and symptoms of hip OA, regulatory agencies prefer
assessment of pain, function and patient assessment of global
impact, and all three must be signiﬁcantly superior as compared to
SOC or placebo4. However, in the US, drugsmay be approved for the
treatment of OA pain by demonstrating a clinically meaningful and
statistically signiﬁcant pain response while the functional assess-
ment and patient global need not be statistically signiﬁcantly bet-
ter, but they cannot worsen5,95.
For device approvals, the importance of efﬁcacy is secondary to
the safety of the device from the regulatory agency perspective;
however, to determine efﬁcacy in terms of pain relief and func-
tional improvement, a numerical rating scale (NRS) for pain, the
Western Ontario and McMasters Universities (WOMAC) pain and
function measures as well as the Hip Disability and Osteoarthritis
Outcome Score (HOOS) outcome instrument have been used6.
These instruments are described in more detail in Section D.
Study subject requirements: entering patients in hip OA
clinical trials
This section addresses several aspects of the study design,
including the protocol, admission criteria, and selection of the
study population and the deﬁnition of what is to be studied.
Overview of the protocol
The study protocol should be divided into sections that
encompass background information, rationale for the study, the
question(s) being asked, size and site(s) of the study, method of
patient selection (including inclusion and exclusion criteria), the
study methods including clearly deﬁned primary and secondary
outcome variables, speciﬁc measures to be performed at each visit,
drug dispensing format, method of reporting adverse events, sta-
tistical analysis and regulatory issues (including drug account-
ability, institutional requirements, etc.). The protocol (Table I)
should carefully deﬁne the investigators, their study sites, the
method of randomization, patient monitoring procedures, tech-
nical aspects of imaging techniques, laboratory tests, methods of
documenting adverse events, methods of blinding, method of
documenting medication intake for each patient (active drug, pla-
cebo, rescue analgesia), and the method of maintaining the medi-
cation log for each participating center.Demographics
Subject characteristics and other demographic information
recorded should include age (date of birth), weight, height, and
body mass index (BMI), gender, race/ethnicity, co-morbid medical
conditions, medication history, marital status, type of insurance
and years of formal education, history of participation in elite,
extreme or professional sports should be elicited.
Diagnosis
Criteria for diagnosis of hip OA should be clearly stated. Patients
should fulﬁll criteria for the classiﬁcation of OA, such as those
published by the American College of Rheumatology (ACR)7. The
disease should be classiﬁed as idiopathic (primary) or secondary.
Study populations should be as homogenous as possible with re-
gard to the presence of idiopathic (primary) or secondary OA1,7. If
patients with secondary OA are studied, the underlying condition
should be speciﬁed and should be the same in all patients (e.g.,
post-traumatic OA, femoroacetabular impingement [FAI]). It is
suggested that in studies of patients with idiopathic OA, exclusions
should include not only inﬂammatory arthropathies but also sec-
ondary OA of the study joint.
Baseline information about the index joint helps to characterize
the study population and provides reference data for assessing how
variables of interest have changed during the course of treatment.
This should include measurement of pain and self-reported func-
tion using a reliable, valid and responsive instrument such as the
WOMAC8 OA index or Hip Osteoarthritis Outcome Score (HOOS)12.
See Section D for further description of outcome instruments.
Radiographs
The radiographic severity of OA in each patient should be
quantiﬁed and documented using either a valid radiographic scale
(e.g., Kellgren and Lawrence grade9 or Croft scale10) or grading of
speciﬁc individual radiographic features (e.g., OARSI Atlas11). The
radiographic entry criteria should also be appropriate for the spe-
ciﬁc study design. For example, a cohort that included advanced
severity might be appropriate in studies of a symptom modifying
drug while a cohort limited to minimal severity would be more
appropriate for studies of a structure modifying drug intended to
slow progression.
Study population
Inclusion criteria should be clearly deﬁned and should specify
the population to be studied by age, clinical diagnosis and classi-
ﬁcation criteria, severity of symptoms, and radiographic grade (vide
supra). Exclusion criteria should similarly be clearly deﬁned with
regard to concomitant diseases, concomitant medications, and
secondary OA.
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tential should be screened for pregnancy, and if pregnant, should be
excluded from the trial.
Symptom modifying treatments
For studies of symptomatic response, the level of symptoms at
baseline should be of sufﬁcient severity to permit detection of
change (e.g., a minimum pain score of 4 on a 0e10 NRS). Inclusion
criteria for symptomatic response should include the following:
 Pain of at least moderate intensity: e.g., visual analog scale (VAS)
recording of 40 mm (0e100 mm); or NRS of 4 (0e10 units);
 Deﬁnite radiographic changes of OA, using an established scale
and atlas, e.g., KellgreneLawrence grade 2 or modiﬁed Croft
scale 210e12.Structure modifying treatments
For studies of structure modifying drugs, enriching for special
subpopulations of subjects who are at high risk for development or
progression of OA within the window of opportunity for mea-
surement (usually not more than 2 years) of a clinical trial may be
advantageous. In addition, the following should be considered:
Kellgren and Lawrence radiographic entry criteria: prevention
studies: grades 0 or 1 (i.e., absence of both a deﬁnite osteophyte and
deﬁnite joint space narrowing (JSN)); structure modiﬁcation
studies: grades 2 or 3 (i.e., sufﬁcient remaining interbone distance
to permit detection of worsening/progression). Current pain in the
index joint is essential, as improvement in clinically relevant
symptoms is presently required as a co-primary endpoint by reg-
ulatory bodies in both US and Europe for approval of a disease
modifying OA drug (DMOAD), i.e., for both structure and symptom
modiﬁcation.
Physical examination
A general physical examination should be performed at the
onset of the study and again at the end of the study.
Examination of the hip joint itself, with assessment of such
parameters as range of motion (ROM) and pain on palpation or
ROM, or examination for clinical signs of FAI may be useful, and
when standardized have adequate reliability for research pur-
poses7. For clinical trials of hip OA, the parameters of internal and
external rotation may be the most affected by the disease and these
movements can elicit pain such that they may be used for the
diagnosis and assessment of intervention efﬁcacy and effectiveness.
Also, advanced radiographic hip OA can be accompanied by a
ﬂexion contracture, and notation of this abnormality is important,
as a medical intervention would most likely not inﬂuence this
parameter. Palpation of the greater trochanter and trochanteric
bursa should be performed and noted if pain was elicited.
Informed consent
Guidelines for information to be contained in the Informed
Consent statement should be in accordance with the Declaration of
Helsinki13. Patient participation requires understanding, and
completion of an informed consent document that has been
approved by the appropriate institutional review boards.
Outcome measures
All of the following outcome measures are best expressed as a
change from baseline values. This allows for heterogeneity of the
patient population at baseline.Pain
Pain in the index hip should be assessed, most commonly using
some type of visual analog scale (100mmVAS, 5-point Likert scale, or
11-point NRS14,15). Pain can be assessed in general, over a given time
frame (e.g., 48 h, 1 week), and/or with speciﬁc activities such as
weight bearing [standing or walking], stair climbing, and rest. Reli-
able, valid and responsivemeasures, such as the pain subscales of the
Western Ontario and McMaster Osteoarthritis Index (WOMAC),
HOOS Oxford hip score (OHS) or Harris Hip Score (HHS), can provide
additional,more detailed information relevant to a given study8,15e18.
Themeasure of Intermittent andConstantOsteoarthritis Pain (ICOAP)
is a measure developed speciﬁcally to separately assess intermittent
and constant aspects ofOApain12. Thepsychometric properties of the
ICOAP, HOOS, WOMAC, and NRS are comparable18.
Function
There are several available instruments to assess self-reported
functional status in hip OA patients. The most commonly used valid
and reliable measures are the WOMAC and the HOOS. The HHS and
OHS also assess function and activities of daily living but may not be
as well suited for research purposes18. Assessment of performance-
based function should also be considered (see Section D5).
Patient and physician global assessments
Determination of the global status of the index joint can be
made from the patient and the physician perspective, and can be
assessed using a VAS or Likert scale. The optimal method by which
this should be measured is not well established. However, a stan-
dard patient assessment question such as “Considering all the ways
your hip OA affects you, how are you doing over the past (specify
time frame)?” can be used. The regulatory expectation is for
limiting the amount of recall built into the question. Thus a 24 or
48-h question would be more reliably answered than a 7-day
question. The physician can assess using a question such as:
“Considering all information, how is the patient's hip OA today?1,7
Quality of life
Quality of life assessments are important components of treat-
ment effectiveness in hip OA. The HOOS, mentioned above for pain
and function, also contains subscales focused on quality of life as
well as sports and recreational activities18. The Osteoarthritis Knee
and Hip Quality of Life (OAKHQOL) was speciﬁcally designed for
this purpose and shows good psychometric properties19,20. Other
general measures of quality of life commonly used in arthritis
studies include the Medical Outcomes Study 36 question short
form (SF-36)21e23, the Euroquol (EQ-5D)24,25, and the Assessment
of Quality of Life (AQol)26.
Psychosocial outcomes, such as pain coping Pain Coping In-
ventory27, self-efﬁcacy (Arthritis Self-Efﬁcacy Scale30), fear of
movement (Brief Fear of Movement Scale for Osteoarthritis28), and
symptoms of depression and anxiety (Center for Epidemiologic
Studies-Depression scale29,30, Hospital Anxiety Depression
Scale29,31,34), may also be relevant in some trials, particularly for
symptom-modifying therapies and for studies that examine
mechanistic aspects of patient response and predictors of treat-
ment response32.
Performance-based functional measures
OARSI has published recommendations for performance-based
tests to assess function in persons with hip (and knee) OA. The
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walk test, and a stair climb test. Additional measures that may be of
interest to include the timed up and go test and the 6-min walk
test32e34.
Response criteria
Some measures have deﬁned minimum clinically important
differences (MCIDs). For the WOMAC, a change from baseline
measure of approximately 10 mm on the 100 mm normalized VAS
form was detectable to patients35. In addition, validated measures
such as the OMERACT-OARSI responder criteria36 categorize in-
dividuals as responders (50% or greater improvement in pain or
function and absolute change of at least 20 points, OR at least 20%
and at least 10 point improvements in 2 of 3 [pain, function, patient
global]) or non-responders. This can be used to calculate numbers
needed to treat, which can be useful in economic evaluations. The
concept of percentage of patients who achieve a clinically relevant
improvement threshold measured by a responder analysis has long
been acceptable by regulatory bodies both in Europe and the US.
Molecular biomarkers
Deﬁnition of a biomarker
The US National Institutes of Health (NIH) deﬁnes a biomarker
as “a characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention”. This sec-
tion focuses on the so-called “soluble” or “wet” biomarkers, usually
measured in body ﬂuids such as serum, plasma, urine or synovial
ﬂuids and usually reﬂecting variation of an endogenous substance
(proteins, protein fragments, metabolites, carbohydrate or genomic
biomarkers (RNA or DNA) in these ﬂuids Ideally, soluble biomarkers
should be speciﬁc for one single joint tissue and/or one particular
pathogenic process and should reﬂect metabolic changes occurring
in this particular tissue37. In theory, these existing biomarkers can
be categorized according to the OA process targeted such as
markers of cartilage degradation/synthesis, bone remodeling, and
synovial tissue degradation/activity. A system called BIPEDS clas-
siﬁes the major types of biomarkers according to their clinical in-
formation into six categories: Burden of disease, Investigational,
Prognostic, Efﬁcacy of intervention, Diagnostic and Safety bio-
markers38. The three biomarker categories of prognostic, efﬁcacy of
intervention and safety are the highest development priorities for
OA clinical trials; this is due to the fact that, at present, the diag-
nosis of OA for meeting enrollment criteria is based on established
anatomic abnormalities identiﬁed by an imaging technique such as
plain radiography or magnetic resonance imaging (MRI)39 It is
conceivable that, in the future, OA trials will be conducted on pa-
tients at earlier stages of disease development that might require
diagnostic biomarkers, including serum, urine, synovial or genetic
biomarkers to identify the appropriate patient population and
verify a diagnosis of early OA that would not yet be possible by an
existing imaging technique.
OARSI/FDA biomarker classiﬁcation
More recently, the OARSI/FDAOsteoarthritis BiomarkersWorking
Group has classiﬁed biomarkers into four categories (exploration,
demonstration, characterization and surrogacy levels) according to
their current level of qualiﬁcation for drug development40. At this
time, no biomarkers are considered as surrogate biomarkers of
radiographic features in the development of drugs40e42. By US FDA
criteria, a surrogate biomarker would be a measureable biomarkerwhose responsiveness to therapeutic intervention would be
reasonably likely to predict a response in a relevant clinical outcome.
Anexample of thiswould be blood pressure,where hypertension and
its response to therapies mimic the alteration in risk for stroke and
myocardial infarction as well as death.
Biomarkers and hip OA
Until now, soluble biomarkers have been mainly investigated in
knee OA, and our knowledge of applicability of biochemical
markers in hip OA is limited. In 2010, a systematic review of the
literature scoring biochemical markers according the BIPEDS
criteria, found that only 23% concerned hip OA41. There is a need for
clinical trials and cohorts investigating speciﬁcally hip OA. Recently,
a large scale meta-analysis of urinary and serum biomarkers
including 3583 individuals from the Rotterdam study, the genetics
of osteoarthritis and Progression (GARP) study, the Chingford Study
and the Twins UK cohort concluded that after adjustment for
multiple comparison only urinary C-terminal telopeptide of type II
collagen (CTX-II) was associated with hip OA risk, but not hip OA
severity, while no association was found for serum COMP or
another type II collagen epitope C2M42. However, these data need
to be interpreted with caution since it was demonstrated that
uCTX-II was the only cartilage biomarker correlated with the bone
biomarkers suggesting that uCTX-II more likely reﬂects bone
turnover rather than cartilage metabolism43.
Speciﬁcity of a biomarker or a cluster of biomarkers for one
particular tissue, one particular joint and/or one particular patho-
genic process are key elements for the interpretation of soluble
marker value. In this way, post-translational modiﬁed forms of
matrix proteins, such as Coll2-1NO2 and D-COMP, have been pro-
posed as joint and/or disease speciﬁc biomarkers. Coll2-1NO2 is the
nitrated form of Coll2-1, a denaturation epitope located in the he-
licoidal part of type II collagen44. In serum, Coll2-1NO2, but not
Coll2-1, is correlated with the level of C-reactive protein in both OA
and RA population indicating that Coll2-1NO2 could be used as a
speciﬁc marker of the inﬂammatory reaction occurring in joint45. In
a study of patients undergoing joint replacement, serum deami-
dated COMP (D-COMP), but not total COMP, declined signiﬁcantly
after joint replacement demonstrating a joint tissue source for D-
COMP. In analyses of 450 participants from the Johnston County
Osteoarthritis Project, D-COMP was associated with radiographic
hip OA but not knee OA severity. In contrast, total COMP was
associated with radiographic knee but not hip OA severity. D-COMP
is the ﬁrst biomarker to show some speciﬁcity to a particular joint
site46. Recently, a few studies have reported changes in both serum
and synovial cytokines and other markers of inﬂammation in
subjects with hip OA or FAI compared to control subjects47e50.
We recommend that there should be standardized protocols for
ﬂuid handling, storage, and analysis of the biomarkers to ensure the
data are both reliable and valid. Additional information regarding
recommendations for biomarkers for clinical trials of OA is covered
in ARTICLE X in this special issue.
Evaluation of structural endpoints in SMOAD trials
Radiography [see also Chapter X for additional information on
radiographic protocols and measurements for hip OA]
Plain radiography is widely used to establish the diagnosis and
to evaluate structural outcome in longitudinal DMOAD trials in
persons with hip OA. It is widely available, less complex, although
requiring consistent positioning from study to study and over time,
and less costly than MRI and other modalities, and there is an
extensive literature evaluating its performance. Joint space width
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and is currently the only outcome measure recommended by the
US Food and Drug Administration (FDA) and European Medicines
Agency (EMA) in Europe and Therapeutic Good Administration
(TGA) in Australia for use in osteoarthritis research trials51. In the
hip, JSN over time may be more directly related to cartilage damage
and loss than in the knee, where in the opinion of the authors, a
large component of the apparent JSW reﬂects the integrity and
position of the meniscus52.
Radiographic endpoint (see also Chapter X for additional
information on radiographic protocols and measurements for hip
OA)
Change in quantitative JSW obtained from conventional AP ra-
diographs of the pelvis is the most commonly recommended53,
used and studied measure of hip OA structural outcome. Quanti-
tative JSW, and categorical measurements derived there from, have
superior reliability and responsiveness compared to other metrics
of hip OA radiographic progression, such as KellgreneLawrence
grades and semi quantitative JSN grades54.
Protocol for AP hip radiograph
A weight-bearing AP view of the pelvis (both hips) with the
beam centered on the superior aspect of the symphysis pubis is the
preferred protocol for obtaining a measure of JSW at the critical
points on superior locations of the joint56. The AP pelvis view is also
suitable for assessing the presence and severity of radiographic OA
for determining study eligibility using KellgreneLawrence or semi
quantitative JSN grades53e56. Alternative radiography protocols
(e.g., oblique, frog leg) can evaluate JSN in locations other than the
superior aspect of the joint and when combined with an AP view
may increase sensitivity to detection of JSN and change in JSW57.
Unilateral AP views centered on the hip joint space are sometimes
used in clinical studies and comparative data suggest that reliability
and responsiveness for JSW are comparable to an AP pelvis57,58.
However, these alternative protocols are far less practical since
positioning is more complex and requires ﬂuoroscopy.
Several variations in the AP hip acquisition protocol have been
compared for JSW measurement performance, but the data are
generally not conclusive as to which approaches are superior.
Regardless of the speciﬁc protocol used, the most important
consideration for obtaining high quality structural outcome data is
to ensure that all aspects of the acquisition are carefully stan-
dardized and are identical at all time-points in an individual study
participant.
In theory, weight-bearing helps ensure that the JSW most
closely reﬂects cartilage thickness in the plane of measurement in
the hip. The limited data available tend to support weight-bearing
JSWas more accurate and sensitive for superior JSN in OA hips with
at least moderate OA59,60, but data demonstrating greater reliability
and responsiveness of weight-bearing are not conclusive61. Supine
positioning may have advantages for obese subjects by reducing
interference from abdominal soft tissue. If acquired standing in
obese subjects, it may be necessary to move the panniculus away
from the ﬁeld of view (e.g., using waist bands). Since morbid
obesity is a less frequent comorbidity in patients with hip OA, as
compared to knee OA, weight bearing will be suitable for most
study subjects in a treatment trial, with supine positioning at all
measurement time points as an alternative when needed in obese
subjects.
Whether standing or supine, internal rotation should be stan-
dardized at a selected point somewhere between 10 and 20 for
both feet and replicated precisely over time, since internal rotation
can affect JSW by generating force on the superior articular sur-
faces62,63 and failure to standardize will increase measurementvariability64. Other positional variations, including hip abduction,
adduction and ﬂexion can affect JSW, but may have a greater in-
ﬂuence on ﬁxed location than on the minimum JSW (mJSW)65. A
positioning device to standardize internal rotation of the femur at
10e20 as well as other aspects of positioning between subjects
and over time is preferred, although foot maps have also been used
to replicate internal rotation within subjects over time59. Most
trials and longitudinal studies have imaged both hips together in a
pelvis view with the beam centered on the superior aspect of the
symphysis pubis. Since centering higher on the abdomen tends to
show a larger JSW64,65, care in determining this landmark should be
emphasized.
JSW measurement: reliability, validity, responsiveness and
progression
Quantitative JSW is assessed in a superior region of the hip joint
as the distance between the femoral head bone edge and the
apparent articulating bone edge of superior acetabular, deﬁned by
the bright line, or acetabular sourcil, using either manual or
computer-assisted methods. The mJSW, or the point of maximal
narrowing in the superior region of the joint, has been recom-
mended as the preferred primary structural endpoint in hip OA
DMOAD trials51,53. Most studies evaluating the performance of
different acquisition protocols and measurement techniques have
used mJSW as the standard51,53. Therefore, data on reliability, val-
idity, responsiveness and comparative performance apply largely to
mJSWandmay not be applicable to othermeasurement techniques,
such as JSW in a ﬁxed location or another area of the joint space. It
follows from this that while the performance of mSJW is the best
characterized, there are insufﬁcient data to deﬁnitively support a
claim that it is the most reliable or responsive JSW parameter.
Further studies are needed comparing mJSW with other metrics.
Cross-sectional reliability of measurement methods of hip JSW
is generally good, but shows a wide range across studies, with
interclass correlation coefﬁcients (ICCs) for a measurement on ra-
diographs from single acquisition ranging from 0.78 to 0.98 for
inter-rater and 0.77 to 0.98 for intra-rater57,58,67e70. Intra-rater is
usually better than inter-rater reliability, suggesting that for
methods relying on some degree of observer judgment (including
computer-assisted, semi-automated needing observer interven-
tion), a single well-trained and experienced observer will provide
the highest measurement precision.
Only a few studies have assessed reliability for measurements of
change in mJSW, and as expected reliability is less, sometimes
substantially so, than for cross-sectional measurements58,59.
Moreover, there are no data examining reliability of the entire
measurement system for hip JSW, including repeat radiographs
with repositioning at multiple time points and repeat measure-
ment at each timepoint. In the absence of this real world data on
ability to reliably measure change, trial planning can be based on
data from longitudinal studies of the mean, and standard deviation
(SD), for rates of change and the derived responsiveness.
The mean rate of decline in mJSW in hips with OA varies widely
across studies, from <0.05 mm/yr to 0.3e0.4 mm/yr57,71e79 with the
higher estimates in studies of patients who had moderate to severe
JSN or subsequently undergo THR62,63,72,75. A recent systematic re-
view and meta-analysis of longitudinal hip mJSW responsiveness
(standardized response mean [SRM]) evaluated data from 11 studies
(7 cohorts and 4 RCTs; 4 with manual and 7 computer-assisted
measurement) meeting standard quality criteria91. The overall SRM
was 0.66. The responsiveness was higher in cohorts (SRM ¼ 0.83),
possibly reﬂecting their longer follow-up, than in RCTs where the SD
was 3 times as large as the mean change (SRM ¼ 0.35). Responsive-
ness using computer-assisted measurement was more than twice
that of manual measurements (SRM 1.12 vs 0.47).
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sion of hip OA recommended using the proportion of hips or sub-
jects who progresses the outcome, based on its greater clinical
relevance than differences in mean change53. A recent OARSI-
OMERACT initiative focused on deﬁning hip JSW progressors by
identifying a cutoff, based on a change greater than measurement
error, abovewhich change inmJSWcould be considered relevant for
patients with hip OA79. Four studies identiﬁed a cutoff based on this
statistical criterion, with cutoffs for change ranging from 0.5 mm to
1.0 mm. The wide range of estimates and the fact that none of the
studies took into account all sources of variability in the measure-
ment (e.g., all were based on repeat measurements from the same
radiograph and not repeated acquisitionwith repositioning) led the
panel to conclude that the deﬁnitions of progressors were not
generalizable beyond the individual study and needed to be deter-
mined for each treatment trial based on pilot data that assesses the
inherent variability in the entire measurement process.
Enriching for increased risk of structural progression
There is moderate evidence from both clinical and population
studies that JSN or reduced JSW at baseline predict subsequent
progression of JSN63,81e83. However, the severity of JSN required to
confer increased risk (e.g., mJSW < 2 mm) may indicate structural
damage that is too far advanced to respond to pharmacologic
therapy. The presence of baseline hip pain also predicts structural
progression in population cohort studies78,83, of potential relevance
in a prevention trial. Evidence suggesting that the severity of
baseline pain in patients with symptomatic hip OA predicts sub-
sequent progression is limited78. Femoral head migration is asso-
ciated with a greater risk of structural progression in several
studies85, although this may simply indicate more severe JSN at
study start. Whether any particular pattern (superomedial,
concentric, superolateral) predicts progression is uncertain53,
although there is limited evidence that asymmetric patterns show
faster progression84,85.
MRI
MRI of the hip is now available to evaluate patients with hip OA
for diagnosis, staging of the severity of the disease, and for
assessment of intervention efﬁcacy in clinical trials. MRI has the
ability to visualize all components of the articular joint simulta-
neously. MRI is superior to radiography for research as it allows for
the visualization of many joint structures associated with hip OA
that are not detectable on conventional radiographs. For example,Table II
Semi-quantitative assessment of hip OA
HOAMS SHOMRI
14 articular features 8 features
Cartilage evaluated 9 subregions (range 0e4) Articular cartilage evaluate
femur (n ¼ 4), acetabulum
Bone Marrow Lesion of acetabulum (range 0e18)
and femur (range 0e27)
Bone Marrow Lesions
Subchondral cysts (range 0e3) based on
region affected
Subchondral cysts
Synovitis scored in 4 locations based on thickness
of synovium (0e4)
Joint effusions
Loose bodies
Abnormalities of Ligamenoan MRI can detect bone marrow lesions (BMLs) and synovial
thickening that are associated with hip pain; neither of these joint
abnormalities can be visualized by radiograph.
Technical aspects of applying MRI of the hip in DMOAD trials,
including image acquisition protocols and quality control, are
treated in detail in an accompanying article in this issue86.
Currently, accurate assessment of the hip may be performed with
ﬁeld strength of either 1.5T or 3.0T. Additional information about
articular cartilage can be obtained by using delayed gadolinium
enhanced imaging (DGEMRIC) that can provide information on the
proteoglycan content of the cartilage; however it does carry a risk
from the contrast agent in patients with chronic kidney disease. In
addition, T2 and T1 rho sequence mapping of the articular cartilage
can provide information on articular cartilage composition
(collagen content, water content and proteoglycan deletion),
standardization of methods to acquire T2 and T1rho values be-
tween scanners has not been routinely done such that these tech-
niques are currently exploratory in clinical trials.Semi-quantitative assessment of hip OA (HOAMS and SHOMRI)
(reviewed in Table II)
The initial work in the semi-quantitative assessment of the
whole knee joint byMRI was done by Peterfy et al.86 and this set the
standard for the ﬁeld. Roemer et al. developed a semi-quantitative
assessment of the whole hip joint by MRI and named it the Hip
Osteoarthritis Scoring System or HOAMS87,88. This scoring system is
composed of 14 articular features. The cartilage evaluation is
divided into nine subregions and the acetabular and femoral head
are scored together as separation of both surfaces is not yet prac-
tical on standard MRI scans. Cartilage is scored from 0 to 4 with
0 ¼ normal cartilage, 1 ¼ focal partial thickness defect of 25% of
subregional area affected, 2 ¼ focal full thickness defect of 25% of
subregion affected, 3 ¼ several partial thickness defects or single
but larger superﬁcial detect of >25% of subregion, and 4 ¼ several
large full thickness defects or single full thickness defect >25% of
subregional area affected. BMLs of the subchondral bone of the
acetabulum (n ¼ 6, with scoring range of 0e18) and femur (n ¼ 9,
with scoring range of 0e27) are assessed in 15 subregions. Coronal
and sagittal PD-weighted fat-saturated MR images are used to
evaluate BMLs, and subchondral cysts are graded according to the
volume of the region affectedwith 133% of region, 2¼ 33e66% of
region, and 3  66% of region. Coronal and axial T1-weighted fat
suppressed contrast-enhanced MR images are used to evaluate the
presence of synovitis. Synovitis is scored in four different locations
and the severity is based on the thickness of the synoviumwith 0 orHIMRISS
3 features of Active Lesions
d in 10 subregions,
(n ¼ 6)
Bone Marrow Lesions
Femur scored with 5 center (range 0e45), 5 anterior
(range 0e20), and 5 posterior slices (range 0e20)
for total score 0e65
Acetabulum BMLs e 5 central, 5 anterior, 5 posterior
with range 0e43.
Total range per subject 0e100.
Joint Effusions scored (0e2)
us teres
Sinusitis scored (0e2)
N.E. Lane et al. / Osteoarthritis and Cartilage 23 (2015) 761e771 767physiologic <2 mm, 2e4 mm ¼ Grade 1, >4 mm ¼ Grade 2. The
presence of MRI detected lesions that were moderate to severe
including cartilage damage, synovitis, joint effusion, etc. by HOAMS
were found to be closely associated with the severity of radio-
graphic hip OA as measured by Kellgren and Lawrence grades88.
The investigators reported a non-signiﬁcant association with MRI
features of BMLs and synovitis obtained by HOAMS and hip pain.
The reliability assessment in the research group that developed the
HOAMS system was very good, with an intra-reader and inter-
reader reliability for 15 random cases reported weighted kappas
values of 0.18e0.85 and 0.15e0.85.
A second semi-quantitative scoring systems available for
assessing hip OA with MRI is the Scoring Hip OA with MRI
(SHOMRI). SHOMRI scores 8 features that include the articular
cartilage (acetabulum and femoral head combined), BMLs, sub-
chondral cysts, labral abnormalities, loose bodies, joint effusion and
abnormalities of the ligamentous teres. Ten subregions (6 in the
femur and four in the acetabulum) are used to score the articular
cartilage bone marrow edema patterns, and subchondral cysts88,89.
Initial intra-reader and inter-reader reliability of this new scoring
method was assessed by two radiologists, with intra-class corre-
lation coefﬁcients greater than 90%; Cohen's kappa values and
percent agreement ranged from 0.55 to 0.79 and 66e99%, respec-
tively. The research group also reported signiﬁcant correlations
with the SHOMRI scores and both radiographic scoring and clinical
outcomes89.
Hip Inﬂammation MRI Scoring System (HIMRISS)
A third MRI based scoring system is the HIMRISS that focuses
only on what is described as active lesions, including BMLs and
synovitis or effusions. A BML is deﬁned as an increase in signal
within the bone on STIR sequences, and does not include bone
cysts. The contralateral hip is the normal reference signal for this
assessment using a bladder signal and T1 images to assist with
identiﬁcation of subchondral cysts. The nearest normal bone
marrow is used if the contralateral hip is abnormal or a THR is
present. The femoral BML is scored in ﬁve central (range 0e45), ﬁve
anterior (range 0e20) and ﬁve posterior slices (range 0e20), with a
total range of the femoral BML of 0e65. The acetabular BMLs are
also scored in ﬁve central slices, ﬁve anterior and ﬁve posterior with
a range of 0e43, and a BML scoring range per subject of 0e100.
Effusion and synovitis are scored together with a 0e2 grading on
the same central, anterior and posterior slices, with a total score
ranging from 0 to 3090.
Currently there are no randomized clinical trials that have used
these MRI scoring systems. However a reliability study was
completed with HOAMS and HIMRISS. TwentyMRIs of the hip were
read by six readers. HIMRISS ICCs ranged from 0.52, 0.61, 0.70, and
0.58 for femoral BMLs, acetabular BMLs, effusion and total scores.
For HOAMS summed BMLs and synovitis the ICCs were 0.52 and
0.4692. In another study, the MRI of the hip from 18 subjects
enrolled in an RCTwere assessed at 2 timepoints and inter-observer
change scores were 0.81 and 0.71 for HIMRISS femoral and HOA-
MAS summed BMLs93. Based on these data, the authors concluded
that both HIMRISS and HOAMS scoring systems are feasible and
reliable however further validation is required.
In summary, two semi-quantitative MRI scoring systems are
available for assessing hip OA in clinical trials, and another method,
HIMRISS, is useful for assessing active lesions, including BMLs and
synovitis (Table II). While initial studies of the investigators that
developed the scoring methods for hip OA assessed by MRI
demonstrate very good reliability for these MRI endpoints, addi-
tional work is still required. For example, prior to the introduction
of these scoring methods into clinical trials, detailed teaching
atlases should be developed and both the number of MRI scans andreaders being tested for reliability should be increased. In addition,
a training set ofMRI scans read by highly trained assessors, could be
available and used by new assessors to efﬁciently learn how best to
score the scan abnormalities and to calibrate themselves to the
trained assessors. The introduction of hip MRI into clinical trials as
an imaging endpoint will provide useful information on both the
national history of hip OA and how interventions may change the
tissues within the hip. The interval to assess changes in joint
structures such as volume of the articular cartilage may be shorter
with MRI than with radiographs, although the exact interval in
whichmeaningful change can reliability be determined will require
additional investigation.
Assessment of symptom modifying drugs and devices
The primary objective of symptom-modifying drugs or devices
in clinical trials for hip OA should be improvement of symptoms
from baseline. The duration of the clinical trials should depend
upon the target product proﬁle of the drug or device whose efﬁcacy
is explored in those studies. For drugs or devices with a fast onset of
action, the length of the trial may be as short as 1 week, whereas in
terms of safety follow-up periods of up to 1 year aremandatory. The
efﬁcacy of symptom-modifying drugs or devices should ideally be
compared against placebo. A positive outcome of a trial is based on
the demonstration of a statistically signiﬁcant and clinically
important difference between the scores for improvement of active
treatment and placebo groups. Substantiating efﬁcacy of a
symptom-modifying drug or device may be thwarted by a high
placebo effect, which is well known in OA trials94. For the conduct
of clinical trials and the correct assessment of symptoms, it is
essential that patients should refrain from taking rescue analgesic
medication at least 24e48 h prior to their follow-up-visits.
Given the problems of missing data, use of rescue analgesic
medications and the use of subjective outcomes, it is critical for the
RCTs used for regulatory approval to be carefully constructed with
“a priori” deﬁnitions of the primary outcome(s), analysis of multi-
ple co-primary and secondary outcome measures, rescue analgesic
use, and missing data. In both the US and Europe, the regulatory
agencies consider symptom modifying drugs in OA to be chronic
therapies; thus pivotal double-blind RCTs should be at least 12
weeks in duration. Proof of concept studies, however, might be
shorter.
Disease modifying drugs
According to the guidelines of health authorities (EMA and the
FDA), the efﬁcacy of structure-modifying drugs needs to be deter-
mined with measurement of JSW on X-ray. Measurement of JSW in
the hip appears more correlated with the actual cartilage thickness
as the hip is devoid of a meniscus. However, due to the slow pro-
gression of cartilage loss in OA and small changes in JSW observed
over time and the SD being much higher than the changes of the
mean, in clinical trials for hip OA, follow-up-periods of at least 2
years appear warranted. An example of a study in which JSW was
used as the primary endpoints was performed by Falgarone and
Dougados72. These investigators carried out a study with 446 pa-
tients with hip OA in which study participants were randomized
1:1. In 269 patients who had completed the study (n ¼ 131 (diac-
erein), n ¼ 138 (placebo)), they detected a statistically signiﬁcant
difference (p ¼ 0.042) in the progression of JSW (0.18 ± 0.25 mm vs
0.23 ± 0.23 mm), thus suggesting structure-modifying effects in
terms of slowing progression of hip.
According to regulatory guidelines, measurement of JSW ap-
pears warranted to demonstrate structure-modifying properties of
a disease-modifying agent for the treatment of hip OA. MRI may be
N.E. Lane et al. / Osteoarthritis and Cartilage 23 (2015) 761e771768a more sensitive and a more promising tool as it helps to visualize
changes in both cartilage and bone morphology that are both
pathophysiologically relevant for the genesis and for the progres-
sion of hip OA.
Summary
There has been a dramatic increase in activity related to the
improvement of clinical trials in hip OA in the past 20 years since
the publication of the initial OARSI recommendations2. We have
presented updated recommendations on study design, inclusion
and exclusion criteria, validated radiographic, MRI and clinical
outcomemeasure for clinical trials that focus on hip OA. In addition,
we have provided updated information on potential biomarkers for
clinical trials. This information can be utilized by sponsors of trials
for new therapeutic agents for hip OA.
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